Jul 13, 2023

Treatment with JAK inhibitor for myelofibrosis leads to Mycobacterium marinum skin infection: A case report

Posted by in categories: biotech/medical, food

China: A recent article published in Clinical, Cosmetic and Investigational Dermatology reports the case of mycobacterium marinum skin infection in the left upper limb of a female patient with chronic idiopathic myelofibrosis during ruxolitinib treatment.

“Our case illustrates the diversity of skin infections that may occur during JAK (Janus kinase) inhibitors treatment, and the need for clinical attention to atypical mycobacterial skin infections cannot be ignored,” Xiaonan Chen, Affiliated Hospital of Weifang Medical University, Weifang, People’s Republic of China, and colleagues wrote in their case study.

Mycobacterium marinum is an atypical bacterium, and skin infections that result from it are relatively rare, usually occurring in homemakers who clean and prepare fish for food and workers engaged in seafood processing. The infection often occurs after fish spines, scales, etc., puncture the skin. The JAK/STAT signalling pathway is closely linked with the human immune response to infections. Therefore, JAK inhibitors may induce and exacerbate various conditions in clinical practice.

Leave a reply